tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
PremiumCompany AnnouncementsKyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
4M ago
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
Premium
Company Announcements
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
4M ago
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
Premium
Company Announcements
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
4M ago
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
PremiumCompany AnnouncementsKyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
4M ago
Kura Oncology receives $30M development milestone payment for ziftomenib
Premium
The Fly
Kura Oncology receives $30M development milestone payment for ziftomenib
4M ago
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
Premium
The Fly
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
5M ago
Kyowa Kirin’s Phase 3 Study on KHK4827 for Systemic Sclerosis: Market Implications
PremiumCompany AnnouncementsKyowa Kirin’s Phase 3 Study on KHK4827 for Systemic Sclerosis: Market Implications
8M ago
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema: A Potential Game-Changer
Premium
Company Announcements
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema: A Potential Game-Changer
8M ago
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
Premium
The Fly
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100